Phase 3 Depression and Anxiety Trial, Recruiting (NCT06966401)

Phase 3 Depression and Anxiety Trial, Recruiting NCT06966401 Sponsor: Neurocrine Biosciences Condition: Depression and Anxiety

Printed from Voxsanity (voxsanity.com.au) — NCT06966401 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Depression And Anxiety

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with recurring moderate or severe depression, or long-lasting (persistent) depression.
Your current depression has not improved enough with antidepressant tablets or capsules taken by mouth.
You have been taking oral (by mouth) antidepressants for at least 8 weeks before the study screening appointment.
You are willing and able to follow all the study rules and procedures, as judged by the study doctor.

Who may not be able to join:

You have been diagnosed with another mental health condition in the past year that was the main focus of your treatment (other than depression).
The study doctor considers you to be at immediate risk of harming yourself or others.
There may be additional rules set out in the study plan that could affect eligibility (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 2 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06966401

Sponsor: Neurocrine Biosciences

Phase: Phase 3

Status: Recruiting

Condition: Depression and Anxiety

More information: https://clinicaltrials.gov/study/NCT06966401

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with recurring moderate or severe depression, or long-lasting (persistent) depression.
Your current depression has not improved enough with antidepressant tablets or capsules taken by mouth.
You have been taking oral (by mouth) antidepressants for at least 8 weeks before the study screening appointment.
You are willing and able to follow all the study rules and procedures, as judged by the study doctor.

Who may not be able to join:

You have been diagnosed with another mental health condition in the past year that was the main focus of your treatment (other than depression).
The study doctor considers you to be at immediate risk of harming yourself or others.
There may be additional rules set out in the study plan that could affect eligibility (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 2 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Neurocrine Biosciences

Registry

ClinicalTrials.gov

Start date

16 April 2025

Est. completion

1 May 2029

Where this trial is recruiting

🇧🇪 Belgium 🇧🇬 Bulgaria 🇭🇷 Croatia 🇨🇿 Czechia 🇪🇪 Estonia 🇫🇮 Finland 🇭🇺 Hungary 🇱🇻 Latvia 🇱🇹 Lithuania 🇳🇱 Netherlands 🇵🇱 Poland 🇷🇴 Romania 🇸🇰 Slovakia 🇸🇪 Sweden 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Number of Participants with Treatment-emergent Adverse Events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov